ARCHIVES

Clinical Trial Pathology Improvements Recommended By Group Remaining Actions After Merit Review

This article is from The Cancer Letter archive.

Vol. 05 No. 02 | January 12, 1979

Download PDF Visit The Full Archive

Related Articles

Techniclone Wins Patent For Tumor Necrosis Therapy.

February 25, 2000

NCCS Appointment Marks Transition To New Structure.

March 17, 2000

Bosnian Research Trying To Leave, Asks For More Calls

February 5, 1993

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

March 28, 2014

In Brief: Hospices Urges To Develop Program For AIDs Victims; Companies Give $25,5000 To NCI Fund

October 25, 1985

Reagan Family History Shows String Risk Factor

August 2, 1985